Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?
- PMID: 31640977
- PMCID: PMC6811451
- DOI: 10.1128/AAC.00900-19
Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?
Keywords: Staphylococcus aureus; ceftaroline; clinical outcomes; daptomycin; medical outcomes; vancomycin.
Comment in
-
Reply to Kalil et al., "Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?".Antimicrob Agents Chemother. 2019 Oct 22;63(11):e01347-19. doi: 10.1128/AAC.01347-19. Print 2019 Nov. Antimicrob Agents Chemother. 2019. PMID: 31640978 Free PMC article. No abstract available.
Comment on
-
Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02483-18. doi: 10.1128/AAC.02483-18. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30858203 Free PMC article. Clinical Trial.
References
-
- Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, Yu M, Vasina L, Ouellette K, Zervos M, Nizet V, Sakoulas G. 2019. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63:e02483-18. doi:10.1128/AAC.02483-18. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical